Home » Vical Licenses Three Cancer Vaccine Targets to Merck
Vical Licenses Three Cancer Vaccine Targets to Merck
June 8, 2005
Vical has announced that Merck & Co. has exercised three options under a 2003 amendment to an existing research collaboration and license agreement, granting Merck rights to use Vical's patented nonviral gene delivery technology in cancer vaccine applications.
As a result of the option exercise, Vical will receive payments of $3 million, and further development may lead to milestone and royalty payments to Vical. In addition, Vical has certain co-promotion rights for therapeutic products resulting from the agreement.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct